Tradename | Company | Number | Date | Products |
---|---|---|---|---|
BALVERSA | Johnson & Johnson | N-212018 RX | 2019-04-12 | 3 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
balversa | New Drug Application | 2024-11-11 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
transitional cell carcinoma | — | D002295 | — |
Expiration | Code | ||
---|---|---|---|
ERDAFITINIB, BALVERSA, JANSSEN BIOTECH | |||
2027-01-19 | I-930 | ||
2024-04-12 | NCE |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Urinary bladder neoplasms | D001749 | — | C67 | 1 | 2 | 1 | — | — | 3 |
Non-muscle invasive bladder neoplasms | D000093284 | — | — | — | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 1 | 2 | — | — | 1 | 4 |
Carcinoma | D002277 | — | C80.0 | 1 | 2 | — | — | — | 2 |
Adenocarcinoma | D000230 | — | — | 1 | 1 | — | — | — | 2 |
Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | — | — | 1 |
Urologic neoplasms | D014571 | — | C64-C68 | 1 | 1 | — | — | — | 1 |
Transitional cell carcinoma | D002295 | — | — | 1 | 1 | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Esophageal neoplasms | D004938 | — | C15 | — | 1 | — | — | — | 1 |
Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
Lymphoma | D008223 | — | C85.9 | 2 | — | — | — | — | 2 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Erdafitinib |
INN | erdafitinib |
Description | Erdafitinib, sold under the brand name Balversa, is an anti-cancer medication. It is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) used for the treatment of cancer. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation, proliferation, angiogenesis, and cell survival. Astex Pharmaceuticals discovered the drug and licensed it to Janssen Pharmaceuticals for further development.
|
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COc1cc(OC)cc(N(CCNC(C)C)c2ccc3ncc(-c4cnn(C)c4)nc3c2)c1 |
PDB | — |
CAS-ID | 1346242-81-6 |
RxCUI | — |
ChEMBL ID | CHEMBL3545376 |
ChEBI ID | — |
PubChem CID | 67462786 |
DrugBank | DB12147 |
UNII ID | 890E37NHMV (ChemIDplus, GSRS) |